Fennec Pharmaceuticals Announces New Investigator-Sponsored Study for PEDMARK® in Adult Cancers

summarizeSummary

Fennec Pharmaceuticals announced a new investigator-sponsored study for PEDMARK® to evaluate its use in AYA and adult patients with head and neck and testicular cancers, aiming to expand the drug's market and clinical evidence.

check_boxKey Events

• New Investigator-Sponsored Study Initiated

  The University of Arizona Cancer Center has initiated a Phase I/II open-label trial to evaluate PEDMARK® (sodium thiosulfate injection) as an otoprotectant in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin chemotherapy.

• Expansion of PEDMARK®'s Potential Use

  This study aims to build real-world evidence and expand the understanding of PEDMARK®'s benefits beyond its current FDA-approved indication for pediatric patients, potentially supporting broader clinical adoption and future label expansion for AYA and adult cancer patients.

• Ongoing Research Efforts

  This new study follows the initiation of two other institution-led clinical studies announced in March 2026 and December 2025, demonstrating Fennec's commitment to supporting independent research for PEDMARK®.

auto_awesomeAnalysis

Fennec Pharmaceuticals announced the initiation of a new investigator-sponsored study for its drug, PEDMARK®, at the University of Arizona Cancer Center. This study will evaluate PEDMARK® in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. This is a positive development as it expands the clinical evidence and potential market for PEDMARK® beyond its current pediatric indication, aligning with the company's strategy to support broader clinical adoption and potential label expansion. The company has recently announced other similar institution-led studies, indicating a concerted effort to build real-world data for its key product.